CLDN18.2, a small transmembrane protein with 4 transmembrane domains and two extracellular loops, is overexpressed in a significant proportion of gastric cancers and esophageal adenocarcinomas. The restricted expression makes it a promising target for the treatment of gastric and esophageal adenocarcinoma. CLDN18.2-specific antibodies developed to target CLDN18.2 have exhibited antitumor activity in preclinical models. Nevertheless, the isolation of antibody with desired pharmacological functions and quality control of antibody production had proved difficult due to technical challenges in genertating high quality CLDN18.2 antigen.
KACTUS utilize its unique structure-guided SAMSTM platform to produce the first full-length wild type CLDN18.2 in the world. The bioactivity has been verified by pharmaceutical customers.